[1]邹清靖,陈 燕,吴小玲,等.宫颈癌患者血清FOXQ1 和CEACAM19 表达水平检测的临床早期诊断价值研究[J].现代检验医学杂志,2023,38(03):154-158.[doi:10.3969/j.issn.1671-7414.2023.03.028]
　ZOU Qing-jing,CHEN Yan,WU Xiao-ling,et al.Study on the Clinical Early Diagnostic Value of Serum FOXQ1 and CEACAM19 Expression Levels in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2023,38(03):154-158.[doi:10.3969/j.issn.1671-7414.2023.03.028]
点击复制

宫颈癌患者血清FOXQ1 和CEACAM19 表达水平检测的临床早期诊断价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年03期
页码:
154-158
栏目:
论著
出版日期:
2023-05-15

文章信息/Info

Title:
Study on the Clinical Early Diagnostic Value of Serum FOXQ1 and CEACAM19 Expression Levels in Patients with Cervical Cancer
文章编号:
1671-7414（2023）03-154-05
作者:
邹清靖; 陈 燕; 吴小玲; 居文惠
（荆州市中心医院妇科，湖北荆州 434000）
Author(s):
ZOU Qing-jing;  CHEN Yan;  WU Xiao-ling;  JU Wen-hui
（Department of Gynaecology, Jingzhou Central Hospital, Hubei Jingzhou 434000, China）
关键词:
宫颈癌; 叉头框蛋白; 癌胚抗原相关细胞黏附分子19; 早期诊断
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.03.028
文献标志码:
A
摘要:
目的 探讨血清叉头框蛋白Q1(fork-head box Q1, FOXQ1) 和癌胚抗原相关细胞黏附分子19(carcinoembryonicantigen-related cell adhesion molecule 19, CEACAM19) 联合检测对宫颈癌的早期诊断价值。方法 选取2019 年1 月～ 2022年8 月荆州市中心医院收治的120 例宫颈癌患者、120 例宫颈上皮内瘤变(cervical intraepithelial neoplasias, CIN) 患者分别为宫颈癌组、CIN 组，另选取同期120 例健康体检者为健康组。比较宫颈癌组、CIN 组和健康组血清FOXQ1，CEACAM19 水平；分析血清FOXQ1，CEACAM19 水平与宫颈癌临床病理特征的关系；受试者工作特征(receiveroperating characteristic, ROC) 曲线分析血清FOXQ1 和CEACAM19 对宫颈癌的早期诊断价值；Logistic 回归分析宫颈癌发生的影响因素。结果 与健康组比较，CIN组和宫颈癌组血清FOXQ1（6.48±2.16 ng/ml，11.21±3.74 ng/ml vs 0.52±0.17ng/ml）和CEACAM19（54.93±13.75 ng/L，87.17±21.80 ng/L vs 31.29±7.82 ng/L）水平升高，差异有统计学意义（t=30.133，31.279；16.371，26.431，均P ＜ 0.05）；与CIN 组比较，宫颈癌组血清FOXQ1 和CEACAM19 水平升高，差异有统计学意义（t=11.997，13.703，均P ＜ 0.05）。与高分化比较，低、中分化的宫颈癌患者血清FOXQ1（14.56±4.85 ng/mlvs 7.38±2.46 ng/ml），CEACAM19（96.87±32.29 ng/L vs 76.08±25.36 ng/L）水平升高，差异有统计学意义（t=10.415，3.945，均P ＜ 0.05）。血清FOXQ1，CEACAM19 诊断宫颈癌的曲线下面积(area under curve, AUC) 分别为0.878，0.887，FOXQ1 和CEACAM19 联合诊断宫颈癌的AUC 为0.942，其敏感度和特异度分别为86.7%，92.1%。血清FOXQ1 和CEACAM19 水平升高与宫颈癌发生相关[OR (95%CI) =2.435(1.545 ～ 3.837)，2.382(1.563 ～ 3.630)，P=0.003]。结论 宫颈癌患者血清FOXQ1 和CEACAM19 水平较高，二者联合检测有助于宫颈癌的早期诊断及临床筛查。
Abstract:
Objective To investigate the value of combined detection of serum fork-head box Q1 (FOXQ1) and carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19) in the early diagnosis of cervical cancer. Methods A total of 120 patients with cervical cancer and 120 patients with cervical intraepithelial neoplasias (CIN) treated in Jingzhou Central Hospital from January 2019 to August 2022 were selected as cervical cancer group and CIN group respectively, and 120 healthy people were selected as healthy group in the same period. The levels of serum FOXQ1 and CEACAM19 in cervical cancer group, CIN group and healthy group were compared. The relationship between serum FOXQ1, CEACAM19 levels and clinicopathological characteristics of cervical cancer was analyzed. Receiver operating characteristic (ROC) curve analysis was used to analyze the value of serum FOXQ1 and CEACAM19 in early diagnosis of cervical cancer，and Logistic regression analysis was used to analyze the influencing factors of cervical cancer. Results Compared with the healthy group, the serum FOXQ1 (6.48±2.16 ng/ml, 11.21±3.74 ng/ml vs 0.52±0.17 ng/ml) and CEACAM19 (54.93±13.75 ng/L, 87.17±21.80 ng/L vs 31.29±7.82 ng/L) levels in CIN group and cervical cancer group were significantly higher, and the differences were statistically significant (t=30.133, 31.279; 16.371, 26.431, all P<0.05). Compared with CIN group, the levels of serum FOXQ1 and CEACAM19 in cervical cancer group were significantly higher, the differences were statistically significant (t=11.997, 13.703, all P<0.05). Compared with well differentiated cervical cancer patients, the levels of serum FOXQ1 (14.56±4.85 ng/ml vs 7.38±2.46 ng/ml) and CEACAM19 (96.87±32.29 ng/L vs 76.08±25.36 ng/L) in patients with poorly and moderately differentiated cervical cancer were significantly higher, and the differences were statistically significant (t=10.415, 3.945, all P<0.05). The area under curve (AUC) of serum FOXQ1 and CEACAM19 in the diagnosis of cervical cancer was 0.878 and 0.887, respectively, the AUC of FOXQ1 combined CEACAM19 in the diagnosis of cervical cancer was 0.942, with a sensitivity and a specificity of 86.7%，92.1%，respectively. The increases of serum FOXQ1 and CEACAM19 levels were associated with cervical cancer [OR (95%CI)=2.435(1.545 ～ 3.837), 2.382(1.563 ～ 3.630), P=0.003]. Conclusion The levels of serum FOXQ1 and CEACAM19 in patients with cervical cancer were high. The detection of serum FOXQ1 and CEACAM19 levels is helpful to the diagnosis of early cervical cancer, and the combination of the two is more valuable for the early diagnosis of cervical cancer, which is more helpful for clinical screening of early cervical cancer patients.

参考文献/References:

[1] ROSLIND A, PALLE C, JOHANSEN J S, et al. Prognostic utility of serum YKL-40 in patients with cervical cancer[J]. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80(8): 687-693.
[2] LIN Feng, ZHENG Ruru, YU Chen, et al. Predictive role of serum cholesterol and triglycerides in cervical cancer survival[J]. International Journal of Gynecological Cancer, 2021, 31(2): 171-176.
[3] WANG Wenrong, GAO Xing, ZHU Yuan, et al. Diagnostic significance of a color Doppler ultrasound combined with serum CXCL16 and E-cad in cervical cancer[J]. Translational Cancer Research, 2021, 10(3): 1492-1499.
[4] 方芳, 吴玲, 魏善闯, 等. 宫颈癌患者血清LCN2 水 平表达与HPV 病毒载量及临床分期的相关研究[J]. 现代检验医学杂志, 2022, 37(2): 80-84, 99. FANG Fang, WU Ling, WEI Shanchuang, et al. Correlation of expression of serum LCN2 level with HPV load and clinical stage in patients with cervical cancer [J]. Journal of Modern Laboratory Medicine,2022, 37(2): 80-84, 99.
[5] LI Heyue, LI Linxia, SUN Jianming, et al. Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions[J]. Pakistan Journal of Medical Sciences, 2022,38(6): 1471-1476.
[6] 杨丽菊, 于克, 朱云芳. 宫颈癌组织miR-124-3p、FOXQ1 mRNA表达变化及其临床意义[J].山东医药,2020, 60（34）：65-67. YANG Liju, YU Ke, ZHU Yunfang. Expression of miR-124-3p, FOXQ1 mRNA in cervical carcinoma and its clinical significance[J]. Shandong Medical Journal,2020, 60(34): 65-67.
[7] ZISI Z, ADAMOPOULOS P G, KONTOS C K, et al. Identification and expression analysis of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19) gene using a high-throughput sequencing approach[J]. Genomics,2020, 112(6): 4268-4276.
[8] 中华人民共和国国家卫生和计划生育委员会. 宫颈 癌及癌前病变规范化诊疗指南( 试行)[J]. 慢性病学 杂志, 2013, 14(6): 401-410. National Health and Family Planning Commission of the People’s Republic of China. Guidelines for standardized diagnosis and treatment of cervical cancer and precancerous lesions(trial)[J]. Chronic Pathematology Journal, 2013, 14(6): 401-410.
[9] 张军. 宫颈癌治疗的现状及问题：从临床指南到真 实世界研究[J]. 中国全科医学, 2022, 25(3): 259-263. ZHANG Jun. Current status and challenges of cervical cancer treatment: from clinical guidelines to real-world study[J]. Chinese General Practice, 2022, 25(3): 259-263.
[10] 李海英, 蔡竞, 朱虹丽. 宫颈癌的临床治疗研究进展 [J]. 宁夏医科大学学报, 2020, 42(4): 419-423. LI Haiying, CAI Jing, ZHU Hongli. Progress in clinical treatment of cervical cancer[J]. Journal of Ningxia Medical University, 2020, 42(4): 419-423.
[11] SHA Jing, DU Jing, YANG Jianhong, et al. Changes of serum levels of tumor necrosis factor (TNF-α) and soluble interleukin-2 receptor (SIL 2R) in patients with cervical cancer and their clinical significance[J]. American Journal of Translational Research, 2021,13(6): 6599-6604.
[12] AFTAB M, POOJARY S S, SESHAN V, et al. Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer[J]. Scientific Reports, 2021, 11(1): 10323.
[13] LUO Yunfan, WANG Jie, WANG Fan, et al. FOXQ1 promotes metastasis of nasopharyngeal carcinoma by inducing vasculogenic mimicry via the EGFR signaling pathway[J]. Cell Death Dis, 2021, 12(5): 411.
[14] KIM S H, HAHM E R, SINGH K B, et al. Novel mechanistic targets of forkhead box Q1 transcription factor in human breast cancer cells[J]. Molecular Carcinogenesis, 2020, 59(10): 1116-1128.
[15] 罗燕, 蒋益兰, 李勇敏, 等. 重楼皂苷Ⅰ对结肠癌 HCT116 细胞FOXQ1 及上皮间质转化的影响[J]. 中 国实验方剂学杂志, 2020, 26(11): 119-123. LUO Yan, JIANG Yilan, LI Yongmin, et al. Effect of polyphyllin Ⅰ on transcriptional factor FOXQ1 and epithelial-mesenchymal transition in colorectal cancer cell HCT116[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2020, 26(11): 119-123.
[16] WANG Yuan, CHEN Junwen, WANG Xia, et al. miR- 140-3p inhibits bladder cancer cell proliferation and invasion by targeting FOXQ1[J]. Aging, 2020, 12(20): 20366-20379.
[17] XU Jiapeng, YOU Qing, WEI Ziran, et al. miR-519 inhibits epithelial-mesenchymal transition and biologic behavior of gastric cancer cells by down-regulating FOXQ1[J]. International Journal of Clinical and Experimental Pathology, 2020, 13(3): 425-436.
[18] KIM S H, SINGH S V. The FoxQ1 transcription factor is a novel regulator of electron transport chain complex I subunits in human breast cancer cells[J]. Molecular Carcinogenesis, 2022, 61(3): 372-381.
[19] HU Xiheng, CHEN Mingfeng, LI Yangle, et al. Aberrant CEACAM19 expression is associated with metastatic phenotype in penile cancer[J]. Cancer Management and Research, 2019, 11: 715-725.
[20] ZHAO Hongying, XU Jianjun, WANG Yu, et al. Knockdown of CEACAM19 suppresses human gastric cancer through inhibition of PI3K/Akt and NF-κB[J]. Surgical Oncology, 2018, 27(3): 495-502.
[21] 于秀艳, 田春迎, 张晓伟, 等. 血清SBEM, hMAM 和CEACAM19 水平在乳腺癌早期诊断中的临床意 义[J]. 吉林大学学报( 医学版), 2021, 47(6): 1518- 1525. YU Xiuyan, TIAN Chunying, ZHANG Xiaowei, et al. Clinical significances of serum levels of SBEM, hMAM and CEACAM19 in early diagnosis of breast cancer[J]. Journal of Jilin University(Medicine Edition), 2021,47(6): 1518-1525.

相似文献/References:

[1]田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
　TIAN Ying,WANG Shuang-yong,ZHAO Ya,et al.Study on Correlation and Expression of Numb Gene in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
[2]顾益凤,朱自力,史跃燕,等.血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究[J].现代检验医学杂志,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
　GU Yi-feng,ZHU Zi-li,SHI Yue-yan,et al.Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
[3]陈 慎,杜明君,宋雅琴.宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析[J].现代检验医学杂志,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
　CHEN Shen,DU Ming-jun,SONG Ya-qin.Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
[4]周　静,李　智,周　玉,等.宫颈癌组织中 Ep-CAM和 Ki67的表达及临床意义[J].现代检验医学杂志,2019,34(06):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
　ZHOU Jing,LI Zhi,ZHOU Yu,et al.Expression and Clinicd Value of Ep-CAM and Ki67 in the Cervial Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2019,34(03):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
[5]徐晓锋a,王　纯b,卢国丰a,等.宫颈癌患者 Kruppel 样因子 6，p21 蛋白表达水平与病理特征及化疗敏感性的相关性分析[J].现代检验医学杂志,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
　XU Xiao-feng a,WANG Chun b,LU Guo-feng a,et al.Correlation Analysis of KLF6 and p21 Protein Expression Levels andPathological Features and Chemotherapy Sensitivity in Patientswith Cervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
[6]高红敏,杨红英,刘　鑫.血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J].现代检验医学杂志,2020,35(06):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
　GAO Hong-min,YANG Hong-ying,LIU Xin.Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
[7]赵白信,于慧娟,焦方杰,等.经阴道彩色多普勒超声联合血清 miR-130a，miR-425-5p 水平检测对宫颈癌的诊断效能分析[J].现代检验医学杂志,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
　ZHAO Bai-xin,YU Hui-juan,JIAO Fang-jie,et al.Analysis of Diagnostic Efficacy of Transvaginal Color Doppler UltrasoundCombined with Serum miR-130a and miR-425-5p Levels in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
[8]张治洋,李功娟.10株宫颈癌细胞系中MALAT1的表达及其对顺铂敏感性的影响[J].现代检验医学杂志,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
　ZHANG Zhi-yang,LI Gong-juan.Expression of MALAT1 in 10 Cervical Cancer Cell Lines and Its Effect onCisplatin Sensitivity[J].Journal of Modern Laboratory Medicine,2021,36(03):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
[9]郝艳芳,刘亚荣,黄玲玲,等.miRNA-195靶向调控 CCND2和 MYB抑制宫颈癌细胞增殖、迁移的机制研究[J].现代检验医学杂志,2022,37(01):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
　HAO Yan-fang,LIU Ya-rong,HUANG Ling-ling,et al.Study on the Mechanism of miRNA-195 Targeting CCND2 and MYB to Inhibit the Proliferation and Migration of Cervical Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(03):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
[10]方　芳,吴　玲,魏善闯,等.宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究[J].现代检验医学杂志,2022,37(02):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
　FANG Fang,WU Ling,WEI Shan-chuang,et al.Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(03):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]

备注/Memo

备注/Memo:
作者简介：邹清靖（1987-），女，硕士研究生，主治医师，研究方向：妇科肿瘤，E-mail：zqj010@163.com。
更新日期/Last Update: 2023-05-15